Silence Therapeutics website uses cookies. By continuing to browse you are agreeing to our use of cookies.
Channelling gene silencing to cure disease.
Our management team is highly experienced in a variety of relevant sectors, from molecular biology and genetics to pharmaceutical development, BD deals and corporate finance.
Our mission is to use our technology to create a new generation of therapeutics which can improve outcomes for patients and, in the process, build shareholder value.
Silence Therapeutics strives to conduct its business in an ethical, responsible and transparent manner.
Our Board of Directors is formed by five accomplished members, one Executive and four Non-Executive Directors.
We aim to stay in the frontline of the fast-moving field of oligonucleotide therapeutics. Our Scientific Advisory Board (SAB) is a group of world-leading experts in drug discovery and clinical development with particular expertise in the rare disease space. The SAB challenges us to excel at siRNA molecular design, drug discovery, and development
We offer a vibrant culture and environment where innovation and creativity is encouraged.
Download the Corporate Presentation here
Our technology is a highly specific and modular platform that enables us to inhibit or ‘silence’ the expression of disease-causing genes, allowing cells to revert to their healthy state.
We are committed to creating collaborations that maximise value for each of the partners.
We have established, maintained and actively pursue intellectual property protection for our technology.
Discover how our siRNA based therapies work
Effective siRNA delivery to the right cells is a challenge given the complexity of the human body. Discover how we address this.
Find out more about our investment case, share price, corporate governance and related information. Download our latest reports and announcements.
View and download our Results, reports & presentations.
A summary of relevant information for our shareholders, investor FAQs and key adviser details.
Read more about our exisiting corporate governance arrangements.
AIM Rule 26 checklist.
All regulatory news.
Share price information and major shareholders.
Login or Register to our email alerts.
View our latest news, publications and videos here.
View our Latest News here.
Upcoming and past events.
View our Press Coverage here.
View our Publications here.
View our Videos here.
